Mirra is a company.
Mirra has raised $8.0M across 1 funding round.
Key people at Mirra.
Mirra was founded by Kevin Farnham (Founder & CEO).
Mirra has raised $8.0M in total across 1 funding round.
Key people at Mirra.
Mirra was founded by Kevin Farnham (Founder & CEO).
Mirra has raised $8.0M in total across 1 funding round.
Mirra's investors include Accel.
Mirrabooka Investments Limited (ASX: MIR), commonly referred to as Mirra, is a publicly listed investment company based in Melbourne, Australia, specializing in small- and mid-cap value stocks outside the ASX top 50 by market capitalization.[1][2] Its mission centers on delivering attractive long-term returns to investors by targeting undervalued companies in Australia and New Zealand public equity markets, particularly those with low price-earnings ratios, high dividend yields, and strong growth potential in sectors like industrials, healthcare, banks, and materials.[1][2] The firm employs a bottom-up, fundamental analysis approach, blending in-house and external research, with a medium- to long-term buy-and-hold philosophy while remaining nimble on risk management.[1][2] In the startup and broader ecosystem, Mirrabooka supports smaller listed companies, which often include emerging growth stories, by providing patient capital amid higher volatility and liquidity challenges typical of this segment.[2]
Mirrabooka Investments was founded in April 1999 and listed on the ASX on June 28, 2001.[1][2] Key leadership includes CEO and Managing Director Robert Mark Freeman (AMP INSEAD, B.E., Gr.Dip AppFin, M.B.A.) and CFO Andrew J.B. Porter (F.C.A., M.A., M.A.I.C.D.).[1] The firm's focus has evolved around specializing in small- and mid-cap companies in Australia and New Zealand, emphasizing value investing in a volatile segment that requires intensive research and monitoring.[2] This niche arose from recognizing opportunities in overlooked stocks with merger potential and sector-specific strengths, building a track record of long-term holdings since inception.[2]
Mirrabooka rides the trend of value investing in Australia's small- and mid-cap ecosystem, where smaller listed firms—including tech-adjacent players in industrials and healthcare—benefit from post-pandemic recovery and sector consolidation.[1][2] Timing aligns with market forces like rising M&A activity and dividend-seeking amid economic volatility, favoring undervalued growth stories outside mega-caps.[2] By channeling capital into these companies, it bolsters the ASX's mid-tier liquidity and innovation pipeline, indirectly influencing the startup-to-public transition for high-potential ventures in Australia and New Zealand.[2]
Mirrabooka is poised to capitalize on small-cap rebounds, with potential tailwinds from interest rate stabilization and sector-specific booms in healthcare and materials.[1][2] Trends like AI-driven industrials and sustainable banking could amplify its portfolio, though volatility demands vigilant risk management.[2] Its influence may grow as a go-to for patient value plays, evolving toward more tech-infused small-caps while anchoring Australia's investment landscape for undervalued gems.[2] This positions Mirra as a steady force amid broader market rotations back to fundamentals.
Mirra has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in March 2004.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2004 | $8.0M Series A | Accel |